G1 Therapeutics (GTHX) Stock Forecast, Price & News

G1 Therapeutics (NASDAQ:GTHX) Frequently Asked Questions

Is G1 Therapeutics a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for G1 Therapeutics in the last twelve months. There are currently 1 sell rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" G1 Therapeutics stock.
View analyst ratings for G1 Therapeutics or view top-rated stocks.

When is G1 Therapeutics' next earnings date?

G1 Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for G1 Therapeutics.

How were G1 Therapeutics' earnings last quarter?

G1 Therapeutics, Inc. (NASDAQ:GTHX) announced its quarterly earnings data on Wednesday, May, 4th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.98) by $0.17. G1 Therapeutics had a negative net margin of 708.20% and a negative trailing twelve-month return on equity of 107.75%. During the same quarter in the prior year, the company posted ($0.65) earnings per share.
View G1 Therapeutics' earnings history.

What price target have analysts set for GTHX?

6 equities research analysts have issued 12-month price targets for G1 Therapeutics' shares. Their forecasts range from $19.00 to $71.00. On average, they expect G1 Therapeutics' stock price to reach $39.33 in the next year. This suggests a possible upside of 768.3% from the stock's current price.
View analysts' price targets for G1 Therapeutics or view top-rated stocks among Wall Street analysts.

Who are G1 Therapeutics' key executives?

G1 Therapeutics' management team includes the following people:

• Mr. John E. Bailey Jr., CEO, Pres & Director (Age 57, Pay $215.95k)
• Ms. Jennifer K. Moses CPA, Chief Financial Officer (Age 47, Pay $548.18k)
• Dr. Mark A. Velleca M.D., Ph.D., Sr. Advisor & Director (Age 58, Pay $921.86k) (LinkedIn Profile)
• Dr. Rajesh K. Malik Ch.B., M.B., M.D., Chief Medical Officer and Sr. VP of R&D (Age 63, Pay $581.3k)
• Mr. Mark Avagliano, Chief Bus. Officer (Age 46, Pay $601.06k)
• Mr. Terry L. Murdock, Chief Operating Officer (Age 62)
• Mr. Alexander D. Smith M.S., VP of Technical Operations
• Dr. Jay C. Strum Ph.D., Chief Scientific Officer (Age 58)
• Mr. William C. Roberts, VP of Investor Relations & Corp. Communications (Age 53)
• Mr. Blake Jensen, VP of Quality & Compliance

Who are some of G1 Therapeutics' key competitors?

Some companies that are related to G1 Therapeutics include Organogenesis (ORGO), Chinook Therapeutics (KDNY), Erasca (ERAS), Mirum Pharmaceuticals (MIRM), Avid Bioservices (CDMO), Phibro Animal Health (PAHC), Nektar Therapeutics (NKTR), Deciphera Pharmaceuticals (DCPH), Avidity Biosciences (RNA), IGM Biosciences (IGMS), Merus (MRUS), Catalyst Pharmaceuticals (CPRX), Rocket Pharmaceuticals (RCKT), MorphoSys (MOR) and Northwest Biotherapeutics (NWBO).
View all of GTHX's competitors.

What other stocks do shareholders of G1 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD), Kadmon (KDMN), VBI Vaccines (VBIV), Novavax (NVAX) and Pfizer (PFE).

When did G1 Therapeutics IPO?

(GTHX) raised $101 million in an IPO on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

What is G1 Therapeutics' stock symbol?

G1 Therapeutics trades on the NASDAQ under the ticker symbol "GTHX."

Who are G1 Therapeutics' major shareholders?

G1 Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include State Street Corp (8.61%), BlackRock Inc. (7.73%), Fisher Asset Management LLC (5.41%), JPMorgan Chase & Co. (4.91%), Vanguard Group Inc. (4.50%) and Dimensional Fund Advisors LP (1.33%). Company insiders that own G1 Therapeutics stock include Glenn P Muir, James S Hanson, John E (Jack) Jr Bailey, Mark A Velleca, Mark A Velleca, Rajesh Malik and Seth Rudnick.
View institutional ownership trends for G1 Therapeutics.

Which institutional investors are selling G1 Therapeutics stock?

GTHX stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Vanguard Group Inc., Citigroup Inc., JPMorgan Chase & Co., UBS Group AG, Golden Green Inc., Northern Trust Corp, and Qube Research & Technologies Ltd. Company insiders that have sold G1 Therapeutics company stock in the last year include James S Hanson, John E (Jack) Jr Bailey, Mark A Velleca, and Seth Rudnick.
View insider buying and selling activity for G1 Therapeutics or view top insider-selling stocks.

Which institutional investors are buying G1 Therapeutics stock?

GTHX stock was bought by a variety of institutional investors in the last quarter, including Pinz Capital Management LP, Raymond James & Associates, Goldman Sachs Group Inc., Fisher Asset Management LLC, Dimensional Fund Advisors LP, Dynamic Technology Lab Private Ltd, Graham Capital Management L.P., and Federated Hermes Inc.. Company insiders that have bought G1 Therapeutics stock in the last two years include Glenn P Muir, and James S Hanson.
View insider buying and selling activity for G1 Therapeutics or or view top insider-buying stocks.

How do I buy shares of G1 Therapeutics?

Shares of GTHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is G1 Therapeutics' stock price today?

One share of GTHX stock can currently be purchased for approximately $4.53.

How much money does G1 Therapeutics make?

G1 Therapeutics has a market capitalization of $193.48 million and generates $31.48 million in revenue each year. The company earns $-148.35 million in net income (profit) each year or ($4.03) on an earnings per share basis.

How many employees does G1 Therapeutics have?

G1 Therapeutics employs 148 workers across the globe.

What is G1 Therapeutics' official website?

The official website for G1 Therapeutics is www.g1therapeutics.com.

How can I contact G1 Therapeutics?

G1 Therapeutics' mailing address is 700 Park Offices Drive Suite 200, Research Triangle Park NC, 27709. The company can be reached via phone at (919) 213-9835, via email at [email protected], or via fax at 919-741-5830.